✦ LIBER ✦

Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial

✍ Scribed by Koumakis, George; Demiri, Matina; Barbounis, Vassilios; Vassilomanolakis, Michail; Gontikakis, Emmanuel; Pamouksoglou, Philip; Dahabre, Jabrahel; Efremidis, Anna P

Book ID: 118570744
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 63 KB
Volume: 35
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(01)00441-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of weekly paclitaxel an

A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma

✍ Peter G. Rose; Mary Smrekar; Nancy Fusco 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Mature Results of a Phase II Trial of Ge

Mature Results of a Phase II Trial of Gemcitabine/Paclitaxel Given Every 2 Weeks in Patients with Advanced Non–Small-Cell Lung Cancer

✍ Antoinette J. Wozniak; Kimberly Belzer; Lance K. Heilbrun; Omer Kucuk; Shirish G 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 125 KB

A Phase I study of raltitrexed and pacli

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

✍ Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Ma 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of a

Phase II Trial of Capecitabine and Weekl

Phase II Trial of Capecitabine and Weekly Paclitaxel in Patients with Metastatic Breast Cancer Previously Treated with Every-3-Week Taxane Therapy

✍ Joanne L. Blum; E. Claire Dees; Svetislava J. Vukelja; Mammo Amare; David P. Gil 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 111 KB

Phase-II study of weekly schedule of tra

Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28

✍ M. Ruiz; J. Salvador; J. Bayo; M. Lomas; A. Moreno; M. Valero; R. Bernabé; D. Vi 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 245 KB

P-251 Randomized phase II trial of weekl

P-251 Randomized phase II trial of weekly carboplatin/paclitaxel (C/P) versus every-3-week C/P in advanced non-small cell lung cancer (NSCLC): A pure schedule trial

✍ Socinski, Mark A.; Hensing, Thomas A.; Escudero, Miluska; Tynan, Maureen; Baggst 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 340 KB